^
    Back
    Association details:
    Biomarker:PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    J Cancer Res Clin Oncol
    Title:

    Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

    Published date:
    02/01/2021
    Excerpt:
    ...1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive...R/M-NSCLC treated with pembrolizumab or nivolumab...In multivariable analysis, concordance of TPS ≥ 50% in both PD-L1 assays and the development of immune-related adverse events (irAEs) were two significant predictors of better ORR, PFS, and OS. EGFR mutation could also predict significantly worse OS outcomes.
    DOI:
    10.1007/s00432-021-03527-4
    Test:
    PD-L1 IHC 22C3 pharmDx, VENTANA PD-L1 (SP263) Assay
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Signal Transduct Target Ther
    Title:

    Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

    Published date:
    12/06/2023
    Excerpt:
    Among the 46 patients resected in the trial, a significantly higher incidence of MPR in the N/C group was observed than that in the N group among the patients with ≥ 50% PD-L1 expression (80.0% vs.18.2%, odds ratio = 14.85, 95% CI 1.50–64.91, p = 0.009).
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1038/s41392-023-01700-4
    Trial ID:
    NCT04015778
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Overall survival in high and very high PD-L1 expressing patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors in a real-world data setting.

    Published date:
    05/28/2020
    Excerpt:
    ...positive for PD-L1 expression when treated with immune checkpoint inhibitors (ICI), including pembrolizumab (Pb) and nivolumab (Nb)....Results suggest OS benefit for real-world ICI-treated aNSCLC patients with PD-L1 TPS ≥50%, consistent with observations in clinical trials.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e15156
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-IO 2019
    Title:

    A STUDY ON ANALYSIS OF CLINICAL EFFICACY FACTOR AND EXPLORING PROGNOSTIC FACTORS FOR REIMBURSEMENT POLICY AFTER IMMUNOTHERAPY BEING INTRODUCED IN SOUTH KOREA

    Published date:
    12/12/2019
    Excerpt:
    1181 patients, No. of treatment was 10.5 and 7.9 for nivolumab and pembrolizumab separately...Factors associated with response were Smoking (+), Previous RT (-), irAE(+) and PD-L1 over 50%(+), for OS were PS(+), EGFR(-), Previous RT(-) and irAE(+)…
    DOI:
    10.1093/annonc/mdz449